4.055

1.21% -0.065

Tscan Therapeutics Inc (TCRX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$4.12

Aprire:

$4.13

Volume 24 ore:

156.52K

Relative Volume:

0.71

Capitalizzazione di mercato:

$211.88M

Reddito:

$21.05M

Utile/perdita netta:

$-89.22M

Rapporto P/E:

-1.4031

EPS:

-2.89

Flusso di cassa netto:

$-64.50M

1 W Prestazione:

-15.56%

1M Prestazione:

-22.77%

6M Prestazione:

-56.14%

1 anno Prestazione:

-2.63%

Intervallo 1D:

$3.93

$4.1679

Intervallo di 1 settimana:

$3.93

$4.85

Portata 52W:

$3.73

$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Nome

Tscan Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

857-399-9500

Indirizzo

880 WINTER STREET, WALTHAM

Dipendente

199

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

TCRX's Discussions on Twitter

Confronta TCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TCRX	4.0436	211.88M	21.05M	-89.22M	-64.50M	-2.89
VRTX	449.81	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	745.47	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	594.70	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	245.78	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.70	24.89B	3.30B	-501.07M	1.03B	11.54

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-16	Iniziato	BTIG Research	Buy
2024-05-13	Iniziato	Needham	Buy
2023-06-22	Iniziato	Wedbush	Outperform

Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie

04:19 AM

LMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

04:19 AM

Nov 20, 2024

Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India

Nov 20, 2024

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN

Nov 20, 2024

Nov 19, 2024

Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com

Nov 19, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 19, 2024

Nov 16, 2024

FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World

Nov 16, 2024

Nov 15, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria

Nov 14, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India

Nov 14, 2024

TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World

Nov 14, 2024

Nov 13, 2024

TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024

Nov 12, 2024

Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada

Nov 12, 2024

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 12, 2024

Nov 07, 2024

New Blood Cancer Treatment Shows Continued Response - Streetwise Reports

Nov 07, 2024

Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register

Nov 07, 2024

Nov 06, 2024

TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 06, 2024

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Nov 06, 2024

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St

Nov 06, 2024

TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia

Nov 06, 2024

Nov 05, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire

Nov 05, 2024

TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan

Nov 05, 2024

Nov 04, 2024

Waltham cancer biotech adds to real estate footprint - The Business Journals

Nov 04, 2024

TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World

Nov 04, 2024

Nov 02, 2024

TScan expands Waltham facility with additional lease - Investing.com India

Nov 02, 2024

Nov 01, 2024

TScan expands Waltham facility with additional lease By Investing.com - Investing.com UK

Nov 01, 2024

Oct 26, 2024

Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World

Oct 26, 2024

Oct 21, 2024

The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 21, 2024

Oct 18, 2024

Where are the Opportunities in (TCRX) - Stock Traders Daily

Oct 18, 2024

Oct 15, 2024

BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN

Oct 15, 2024

Oct 08, 2024

Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024

Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Oct 08, 2024

Oct 07, 2024

(TCRX) On The My Stocks Page - Stock Traders Daily

Oct 07, 2024

Oct 06, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat

Oct 06, 2024

Oct 05, 2024

American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Oct 05, 2024

Oct 04, 2024

TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire

Oct 04, 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan

Oct 04, 2024

Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

Oct 04, 2024

Oct 01, 2024